AHSA1

AHSA1 is a co-chaperone that activates the HSP90 ATPase cycle and thereby controls the maturation of HSP90 client proteins across diverse cellular contexts (PMID:38937628, PMID:26796264). It engages HSP90 through its conserved NxNNWHW motif, which stimulates HSP90 ATPase activity and tunes HSP90's apparent affinity for ATP; in metazoans an intrinsic chaperone domain (ICD) immediately preceding this motif autoinhibits stimulation and governs regulated recruitment of HSP90 to clients such as the glucocorticoid receptor, with ICD deletion abolishing both HSP90 and receptor binding (PMID:38937628). AHSA1 is required for HSP90 ATPase stimulation in cancer cells, where loss of AHSA1 lowers HSP90 activity (PMID:26796264). As the activating subunit of AHSA1–HSP90 complexes, it stabilizes and matures client proteins including CDK6 and PSMD2, IFI6 and TGFB1, and the mitochondrial import receptor TOMM70, driving proliferation, drug resistance, and mitophagy (PMID:34991674, PMID:40234395, PMID:40685075). AHSA1 protein levels are themselves controlled by CHK1, which interacts with AHSA1 and suppresses TRIM8-mediated ubiquitination to stabilize the AHSA1–HSP90 complex (PMID:42229233). Beyond HSP90, AHSA1 recruits ERK1/2 to phosphorylate and inactivate caldesmon (CALD1) independently of HSP90 and MEK1/2 (PMID:36230524), and binds DNAJB4 to suppress ER-associated degradation signaling (PMID:41990440).

1. 2013 Medium

   Established that Ahsa1, acting through Hsp90, can modify the severity of a transcription-factor-driven developmental defect, linking the co-chaperone to client-dependent phenotypic outcomes in a whole vertebrate.

   Evidence Zebrafish genetic epistasis in a gata3 mutant HDR-syndrome model with live imaging

   PMID:23720234

   Open questions at the time

   • Does not identify the molecular client mediating the modifier effect
   • Genetic, not biochemical, evidence for the Ahsa1–Hsp90 interaction in this context
2. 2015 Medium

   Showed that AHSA1 is required for HSP90 ATPase activity in cancer cells and positioned it upstream of Wnt/β-catenin signaling, connecting the co-chaperone to a defined oncogenic pathway.

   Evidence siRNA knockdown with HSP90 ATPase assay and western blot of Wnt pathway components in osteosarcoma cells

   PMID:26796264

   Open questions at the time

   • Wnt regulation is correlative — no direct AHSA1/HSP90 client in the pathway identified
   • Single cell-line context
3. 2022 High

   Defined AHSA1 as the activating subunit that channels HSP90 toward specific clients (CDK6, PSMD2) and mapped a druggable binding site (K137) required for HSP90 engagement, providing a structural and therapeutic handle.

   Evidence Reciprocal Co-IP, mass spectrometry, K137 mutagenesis, microscale thermophoresis, and xenograft in multiple myeloma

   PMID:34991674

   Open questions at the time

   • Whether CDK6/PSMD2 stabilization is direct or secondary to global HSP90 activation
   • K137 role in client selectivity versus general HSP90 binding not separated
4. 2022 Medium

   Revealed an HSP90-independent function for AHSA1 as a scaffold recruiting ERK1/2 to phosphorylate and inactivate CALD1, expanding its role beyond classical co-chaperone activity.

   Evidence Co-IP, ERK1/2 inhibitor (SCH772984) rescue, and CALD1 knockdown epistasis in hepatocellular carcinoma in vitro and in vivo

   PMID:36230524

   Open questions at the time

   • Mechanism of AHSA1–ERK1/2 recruitment unresolved
   • MEK1/2 independence of ERK activation not mechanistically explained
5. 2025 Medium

   Extended the AHSA1/HSP90α complex to neuroprotective mitophagy by showing it targets the mitochondrial import receptor TOMM70 in microglia, linking the co-chaperone to mitochondrial quality control.

   Evidence Co-IP, immunofluorescence, siRNA knockdown, geldanamycin inhibition, and MPTP Parkinson mouse model with co-culture

   PMID:40685075

   Open questions at the time

   • Whether TOMM70 is a direct HSP90 client or an indirect effector
   • Mechanistic basis of mitophagy initiation downstream of TOMM70
6. 2025 Medium

   Demonstrated that AHSA1–HSP90AA1 stabilizes IFI6 and TGFB1 to drive Osimertinib resistance, mechanistically connecting co-chaperone activity to acquired drug resistance via client stabilization and Akt signaling.

   Evidence Co-IP, western blot, overexpression/knockdown, and pharmacological inhibition in EGFR-mutated lung adenocarcinoma

   PMID:40234395

   Open questions at the time

   • Direct versus indirect stabilization of IFI6/TGFB1 not distinguished
   • Single tumor-type context
7. 2024 High

   Resolved how metazoan AHSA1 activity is intrinsically autoregulated by identifying the ICD that suppresses NxNNWHW-driven HSP90 ATPase stimulation and controls regulated recruitment to HSP90 and the glucocorticoid receptor.

   Evidence In vitro ATPase assays, ICD/NxNNWHW mutagenesis, and cellular Co-IP

   PMID:38937628

   Open questions at the time

   • Signal or modification that relieves ICD autoinhibition in cells unknown
   • Structural basis of ICD–NxNNWHW interference not defined
8. 2026 Medium

   Identified upstream control of AHSA1 protein stability, showing CHK1 suppresses TRIM8-mediated ubiquitination to stabilize the AHSA1–HSP90 complex and sustain ATPase-driven mitophagy in cardiomyocytes.

   Evidence IP-MS, cardiomyocyte-specific CHK1 overexpression and knockout mouse models, western blot

   PMID:42229233

   Open questions at the time

   • TRIM8 ubiquitination site on AHSA1 not mapped
   • How CHK1 mechanistically blocks TRIM8 unresolved
9. 2026 Medium

   Established a further non-canonical axis in which AHSA1 binds DNAJB4 to suppress ERAD signaling and apoptosis, broadening its effector repertoire beyond HSP90 clients.

   Evidence Co-IP, DNAJB4 knockdown epistasis, overexpression assays, and western blot of ERAD markers in endometrial cancer

   PMID:41990440

   Open questions at the time

   • Whether DNAJB4 binding is HSP90-dependent not tested
   • Direct versus indirect ERAD marker suppression unresolved

• The physiological signals that toggle AHSA1 between ICD-autoinhibited and active states, and the rules determining which HSP90 clients AHSA1 selectively matures across tissues, remain unresolved.
• No structural model of the ICD-active transition in a cellular context
• Client-selectivity determinants undefined
• Integration of HSP90-dependent and HSP90-independent (ERK1/2, DNAJB4) functions unknown